A.I. BURNASYAN FMBC CLINICAL BULLETIN

ISSN 2782-6430 (print)

State Research Center −Burnasyan Federal Medical Biophysical
Center of Federal Medical Biological Agency

The journal is published in Russian.
Format – A4.
The periodicity of the journal is 4 times a year.

Issue №1, 2026

more

A.I. Burnasyan  FMBC clinical bulletin. 2025 № 3

A.E. Korolev, O.M.Uryasev

The Role of Intestinal Microbiota in the Development of Cardiovascular Pathology

Ryazan State Medical University, Ryazan,  Russiа

Contact person: Korolev Artem Evgen’evich: korartevg@ya.ru

Abstract
Relevance:  еhis article examines the role of intestinal microbiota and its metabolites in the development of cardiovascular disease. Despite known classical risk factors, morbidity and mortality from cardiovascular diseases remain high, which emphasizes the need to study new pathogenetic mechanisms, including the influence of gut microflora disorders. Key microbiota metabolites such as trimethylamine-N-oxide, short-chain fatty acids, and lipopolysaccharides involved in the development of atherosclerosis, coronary heart disease, chronic heart failure, and arterial hypertension are reviewed. In intestinal dysbiosis, there is a decrease in the diversity of microbiota species, which contributes to the development of inflammatory processes, increased oxidative stress and decreased protective function of the intestinal barrier. These disorders, in turn, negatively affect the course of cardiovascular diseases, including aggravating their progression.

Conclusion: ьodern studies confirm that the composition of intestinal microbiota and its metabolites can serve as new biomarkers for diagnostics and prognosis of cardiovascular diseases. The development of methods for correction of microbiota composition disorders aimed at modulation of microbial metabolic pathways are promising directions. Individual approach to dysbiosis correction opens new opportunities for personalized prevention and treatment of cardiovascular diseases.

Keywords: intestinal microbiota, dysbiosis, cardiovascular diseases, trimethylamine-N-oxide, short-chain fatty acids

For citation: Korolev AE, Uryasev OM. The Role of Intestinal Microbiota in the Development of Cardiovascular

Pathology. A.I. Burnasyan Federal Medical Biophysical Center Clinical Bulletin. 2025.3:44-50. (In Russian) DOI: 10.33266/2782-6430-2025-3-44-50

 

REFERENCES

  1. Кожевников А.А., Раскина К.В., Мартынова Е.Ю. и др. Кишечная микробиота: современные представления о видовом составе, функциях и методах исследования // Российский медицинский журнал. 2017. Т.25. №17. С.1244-1247 [Kozhevnikov A.A., Raskina K.V., Martynova Ye.Yu., et al. Gut Microbiota: Modern Concepts of Species Composition, Functions, and Research Methods. Rossiyskiy Meditsinskiy Zhurnal = Russian Medical Journal. 2017;25;17:1244-1247 (In Russ.)].
  2. Файзуллина Р.А., Сафина К.А. Значение кишечной микробиоты при заболеваниях сердечно-сосудистой системы // Практическая медицина. 2020. Т.18. №1. С.56-61 [Fayzullina R.A., Safina K.A. The Importance of Intestinal Microbiota in Cardiovascular Diseases. Prakticheskaya Meditsina = Practical Medicine. 2020;18;1:56-61 (In Russ.)].
  3. Thursby E., Juge N. Introduction to the Human Gut Microbiota. Biochemical Journal. 2017;474;11:1823-1836. doi: 10.1042/BCJ20160510.
  4. Cani P.D., Plovier1 H., Van Hul1 M., Geurts1 L., et al. Endocannabinoids – at the Crossroads between the Gut Microbiota and Host Metabolism. Nature Reviews Endocrinology. 2016;12;3:133-143. doi: 10.1038/nrendo.2015.211.
  5. Consortium H.M.P. Structure, Function and Diversity of the Healthy Human Microbiome. Nature. 2012;486;7402:207-214. doi: 10.1038/nature11234.
  6. Wopereis H., et al. The First Thousand Days–Intestinal Microbiology of Early Life: Establishing a Symbiosis. Pediatric Allergy and Immunology. 2014;25;5:428-438. doi: 10.1111/pai.12232.
  7. Singh A.K., Kishore P.S., Khan S. From Microbes to Myocardium: a Comprehensive Review of the Impact of the Gut-Brain Axis on Cardiovascular Disease. Cureus. 2024 Oct 5;16;10:e70877. doi: 10.7759/cureus.70877.
  8. Бельмер С.В., Хавкин А.И., Алешина Е.О. и др. Кишечная микробиота у детей: норма, нарушения, коррекция. М.: Медпрактика-М, 2020. 472 с. [Bel’mer S.V., Khavkin A.I., Aleshina Ye.O., et al. Kishechnaya Mikrobiota u Detey: Norma, Narusheniya, Korrektsiya = Intestinal Microbiota in Children: Norm, Disorders, Correction. Moscow, Medpraktika-M Publ., 2020. 472 p. (In Russ.)].
  9. Карпеева Ю.С., Новикова В.П., Хавкин А.И. и др. Микробиота и болезни человека: возможности диетической коррекции // Российский вестник перинатологии и педиатрии. 2020. Т.65. №5. С.116-125 [Karpeyeva Yu.S., Novikova V.P., Khavkin A.I., et al. Microbiota and Human Diseases: Possibilities of Dietary Correction. Rossiyskiy Vestnik Perinatologii i Pediatrii = Russian Bulletin of Perinatology and Pediatrics. 2020;65;5:116-125 (In Russ.)]. doi: 10.21508/1027-4065-2020-65-5-116-125.
  10. Papadopoulos P.D., Tsigalou C., Valsamaki P.N., et al. The Emerging Role of the Gut Microbiome in Cardiovascular Disease: Current Knowledge and Perspectives. Biomedicines. 2022;10;5:948. doi: 10.3390/biomedicines10050948.
  11. Нестеренко З.В., Хавкин А.И., Новикова В.Н., Листопадова А.П. Кишечная микробиота и болезни сердечно-сосудистой системы // Экспериментальная и клиническая гастроэнтерология. 2022. №.3. С.125-133 [Nesterenko Z.V., Khavkin A.I., Novikova V.N., Listopadova A.P. Intestinal Microbiota and Diseases of the Cardiovascular System. Eksperimental’naya i Klinicheskaya Gastroenterologiya = Experimental and Clinical Gastroenterology. 2022;3:125-133 (In Russ.)]. doi: 10.31146/1682-8658-ecg-199-3-125-133
  12. Ежов М.В. Новые возможности снижения сердечно-сосудистого риска в РФ (пострелиз) XIV Национальный конгресс терапевтов // Российский медицинский журнал. 2019. №12. С. 14-16 [Yezhov M.V. New Opportunities for Reducing Cardiovascular Risk in the Russian Federation (Post-Release) XIV National Congress of Therapists. Rossiyskiy Meditsinskiy Zhurnal = Russian Medical Journal. 2019;12:14-16 (In Russ.)].
  13. Yoshida N., Yamashita T., Hirata K. Gut Microbiome and Cardiovascular Diseases. Diseases. 2018;6;3:56. doi: 10.3390/diseases6030056.
  14. Паспорт федерального проекта «Борьба с сердечно-сосудистыми заболеваниями» [Passport of the Federal Project “Combating Cardiovascular Diseases” (In Russ.)]. URL: https://minzdrav.gov.ru/poleznye-resursy/natsproektzdravoohranenie/bssz
  15. Grigor’eva I.N. Gallstone Disease, Obesity and the Firmicutes / Bacteroidetes Ratio as a Possible Biomarker of Gut Dysbiosis. Journal of Personalized Medicine. 2020;11;1:13. doi: 10.3390/jpm11010013.
  16. Browne H.P. Forster S.C., Anonye B.O., et al. Culturing of ‘Unculturable’ Human Microbiota Reveals Novel Taxa and Extensive Sporulation. Nature. 2016;533;7604:543-546. doi: 10.1038/nature17645.
  17. Heianza Y., Ma W., Manson J.E., et al. Gut Microbiota Metabolites and Risk of Major Adverse Cardiovascular Disease Events and Death: a Systematic Review and Meta-Analysis of Prospective Studies. Journal of the American Heart Association. 2017;6;7:.e004947. doi: 10.1161/JAHA.116.004947.
  18. Lin L., Zhang J. Role of Intestinal Microbiota and Metabolites on Gut Homeostasis and Human Diseases. BMC Immunology. 2017;18:1-25. doi: 10.1186/s12865-016-0187-3.
  19. Yang T., Santisteban M.M., Rodriguez V., et al. Gut Dysbiosis is Linked to Hypertension. Hypertension. 2015;65;6:1331-1340. doi: 10.1161/HYPERTENSIONAHA.115.05315.
  20. Zhu W., Gregory J.C., Org E., et al. Gut Microbial Metabolite TMAO Enhances Platelet Hyperreactivity and Thrombosis Risk. Cell. 2016;165;1:111-124. doi: 10.1016/j.cell.2016.02.011.
  21. WHO. Cardiovascular Diseases (CVDs). URL: https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds).
  22. Sanchez-Rodriguez E., Egea-Zorrilla A., Plaza-Díaz J., et al. The Gut Microbiota and its Implication in the Development of Atherosclerosis and Related Cardiovascular Diseases. Nutrients. 2020;12;3:605. doi: 10.3390/nu12030605.
  23. Ивашкин В.Т., Кашух Е.А. Влияние потребления продуктов, содержащих L-карнитин и фосфатидилхолин, на продукцию проатерогенного метаболита триметиламин-N-оксида и кишечный микробиом у пациентов с ишемической болезнью сердца // Вопросы питания. 2019. Т.88. №4. С.25-33 [Ivashkin V.T., Kashukh Ye.A. Effect of Consumption of Products Containing L-Carnitine and Phosphatidylcholine on the Production of the Proatherogenic Metabolite Trimethylamine-N-Oxide and the Intestinal Microbiome in Patients with Coronary Heart Disease. Voprosy Pitaniya = Nutrition Issues. 2019;88;4:25-33 (In Russ.)]. doi: 10.24411/0042-8833-2019-10038.
  24. Din A.U., et al. Amelioration of TMAO through Probiotics and its Potential Role in Atherosclerosis. Applied Microbiology and Biotechnology. 2019;103:9217-9228. doi: 10.1007/s00253-019-10142-4.
  25. Yeh C.F., et al. Mutual Interplay of Host Immune System and Gut Microbiota in the Immunopathology of Atherosclerosis. International Journal of Molecular Sciences. 2020; 21;22:8729. doi: 10.3390/ijms21228729.
  26. Wassenaar T.M., Juncos V.A., Zimmermann K. Interactions between the Gut Microbiome, Lung Conditions, and Coronary Heart Disease and How Probiotics Affect These. International Journal of Molecular Sciences. 2021;22;18:9700. doi: 10.3390/ijms22189700.
  27. Yao M.E., et al. Trimethylamine-N-Oxide has Prognostic Value in Coronary Heart Disease: a Meta-Analysis and Dose-Response Analysis. BMC Cardiovascular Disorders. – 2020;20:1-9. doi: 10.1186/s12872-019-01310-5.
  28. Драпкина О.М., Жамалов Л.М. Микробиота кишечника—новый фактор риска атеросклероза? Профилактическая медицина. 2022. Т.25. №11. С. 92-97 [Drapkina O.M., Zhamalov L.M. Gut Microbiota – a new Risk Factor for Atherosclerosis? Profilakticheskaya Meditsina = Preventive Medicine. 2022;25;11:92-97 (In Russ.)]. doi: 10.17116/profmed20222511192.
  29. Morrison D.J., Preston T. Formation of Short Chain Fatty Acids by the Gut Microbiota and their Impact on Human Metabolism. Gut Microbes. 2016;7;3:189-200. doi: 10.1080/19490976.2015.1134082.
  30. Драпкина О.М., Кабурова А.Н. Состав и метаболиты кишечной микробиоты как новые детерминанты развития сердечно-сосудистой патологии // Рациональная фармакотерапия в кардиологии. 2020. Т.16. №2. С.277-285 [Drapkina O.M., Kaburova A.N. Composition and Metabolites of Gut Microbiota as New Determinants of Cardiovascular Pathology Development. Ratsional’naya Farmakoterapiya v Kardiologii = Rational Pharmacotherapy in Cardiology. 2020;16;2:277-285 (In Russ.)]. doi: 10.20996/1819-6446-2020-04-02.
  31. Конев Ю.В., Лазебник Л.Б. Роль эндотоксина кишечной микробиоты в патогенезе атеросклероза // Терапия. 2015. №2. С.19-27 [Konev Yu.V., Lazebnik L.B. The Role of Gut Microbiota Endotoxin in the Pathogenesis of Atherosclerosis. Terapiya = Therapy. 2015;2:19-27 (In Russ.)].
  32. Григорьева И.Н. Атеросклероз и триметиламин-N-оксид-потенциал кишечной микробиоты // Российский кардиологический журнал. 2022. Т.27. №9. С.142-147 [Grigor’eva I.N. Atherosclerosis and Trimethylamine-N-Oxide: the Potential of Gut Microbiota. Rossiyskiy Kardiologicheskiy Zhurnal = Russian Journal of Cardiology. 2022;27;9:142-147 (In Russ.)]. doi: 10.15829/1560-4071-2022-5038.
  33. Subramaniam S., Fletcher C. Trimethylamine N-Oxide: breathe New Life. British Journal of Pharmacology. 2018;175;8:1344-1353. doi: 10.1111/bph.13959.
  34. Janeiro M.H., et al. Implication of Trimethylamine N-Oxide (TMAO) in Disease: Potential Biomarker or New Therapeutic Target. Nutrients. 2018;10;10:1398. doi: 10.3390/nu10101398.
  35. Matacchione G., Piacenza F., Pimpini L., Rosati Y., Marcozzi S. The Role of the Gut Microbiota in the Onset and Progression of Heart Failure: Insights into Epigenetic Mechanisms and Aging. Clinical Epigenetics. 2024;16:1. doi: 10.1186/s13148-024-01786-9.
  36. Sawicka-Smiarowska E., et al. Gut Microbiome in Chronic Coronary Syndrome Patients. Journal of Clinical Medicine. 2021;10;21:5074. doi: 10.3390/jcm10215074.
  37. Zhang Z., Cai B., Sun Y., Deng H., Wang H.-W., Qiao Z. Alteration of the Gut Microbiota and Metabolite Phenylacetylglutamine in Patients with Severe Chronic Heart Failure. Frontiers in Cardiovascular Medicine. 2023;9:1076806. doi: 10.3389/fcvm.2022.1076806.
  38. Richards E.M., et al. The Gut, its Microbiome, and Hypertension. Current Hypertension Reports. 2017;19:1-11. doi: 10.1007/s11906-017-0734-1.
  39. Katsimichas T., et al. The Intestinal Microbiota and Cardiovascular Disease. Cardiovascular Research. 2019;115;10:1471-1486. doi: 10.1093/cvr/cvz135.
  40. Durgan D.J. Obstructive Sleep Apnea-Induced Hypertension: Role of the Gut Microbiota. Current Hypertension Reports. 2017;19;4:35. doi: 10.1007/s11906-017-0732-3.
  41. Симаненков В.И. и др. Синдром повышенной эпителиальной проницаемости в клинической практике. Мультидисциплинарный национальный консенсус // Кардиоваскулярная терапия и профилактика. 2021. Т.20. №1. С.121-278 [Simanenkov V.I., et al. Increased Intestinal Permeability Syndrome in Clinical Practice. Multidisciplinary National Consensus. Kardiovaskulyarnaya Terapiya i Profilaktika = Cardiovascular Therapy and Prevention. 2021;20;1:121-278 (In Russ.)]. doi: 10.15829/1728-8800-2021-2758.

Conflict of interest. The authors declare no conflict of interest. 
Financing. The study had no sponsorship.
Contribution. Article was prepared with equal participation of the authors. 
Article received: 13.03.2025. Accepted for publication: 05.04.2025

© 2026 Scientific journal - "Clinical Bulletin of the FMBС im. A.I. Burnasyan"
Scroll to Top